China NMPA Drug Inspection - Jiangxi Minkang Pharmaceutical Co., Ltd. - Orange-red granules

On August 23, 2020, the Ningxia Hui Autonomous Region Drug Administration released Announcement No. 73, detailing the results of the second phase of its 2020 drug quality sampling and inspection program. The inspection encompassed 302 batches of drugs across 96 varieties, including 55 batches of chemical drugs, 124 batches of traditional Chinese medicine (TCM) preparations, and 123 batches of TCM decoction pieces. Notably, all 302 batches were found to be fully compliant with national quality standards, with zero violations or safety issues reported.

The inspections were conducted under the regulatory framework of the 'Drug Administration Law of the People's Republic of China' and the 'Administrative Measures for Drug Quality Sampling and Inspection.' Testing was performed by the Ningxia Hui Autonomous Region Drug Inspection Institute based on the 2015 Edition of the Chinese Pharmacopoeia and other national drug standards. Samples were collected from various sources, including major retail chains like Ningxia Guoda Pharmacy and Yinchuan Laobaixing Pharmacy, as well as regional medical institutions such as the Ningxia Hui Autonomous Region People's Hospital and various community health centers.

Manufacturers whose products were tested included Sinopharm Group Tongjitang (Guizhou) Pharmaceutical, Beijing Yimin Pharmaceutical, and Shanghai Huanghai Pharmaceutical, among others. Because all tested samples met the required specifications, no corrective or punitive actions were mandated. The publication of this report serves as a formal public disclosure to ensure transparency in the drug supply chain and confirm the quality of pharmaceuticals circulating within the region.